Transaction #25980 · Form 4 · 0001193125-25-337179
Enveric Biosciences, Inc. · Stock award · Common Stock
Enveric Biosciences, Inc. · Transacted December 23, 2025 · Filed December 30, 2025
What does this filing report?
An SEC Form 4 filing for Enveric Biosciences, Inc. records a stock award involving Common Stock on December 23, 2025. The reported quantity was 7,633. The filing date is December 30, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Enveric Biosciences, Inc.
- Company CIK
- 0000890821
- Security type
- Non-derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 7,633
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 7,904
- Ownership description
- Not reported
- SEC acceptance time
- Dec 30, 2025, 4:40 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- PASQUALONE FRANK ↗
Director
CIK 0001597334
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
- F2
- On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "January Reverse Stock Split"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the"October Reverse Stock Split" together with the January Reverse Stock Split, the "Reverse Stock Splits"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.